title: Oral Panax notoginseng Preparation for Coronary Heart Disease: A Systematic Review of Randomized Controlled Trials.
abstract: This systematic review aims to evaluate current evidence for the benefit and side effect of oral Panax notoginseng preparation for coronary heart disease (CHD). We included 17 randomized clinical trials (17 papers and 1747 participants). Comparing with no intervention on the basis of conventional therapy, oral Panax notoginseng did not show significant effect on reducing cardiovascular events, but it could alleviate angina pectoris (including improving the symptoms of angina pectoris [RR 1.20; 95% CI 1.12 to 1.28; 7 trials, n = 791], improving electrocardiogram [RR 1.35; 95% CI 1.19 to 1.53; 8 trials, n = 727], decreasing the recurrence of angina pectoris [RR 0.38; 95% CI 0.16 to 0.94; 1 trials, n = 60], duration of angina pectoris [RR -1.88; 95% CI -2.08 to -1.69; 2 trials, n = 292], and dosage of nitroglycerin [MD -1.13; 95% CI -1.70 to -0.56; 2 trials, n = 212]); oral Panax notoginseng had no significant difference compared with isosorbide dinitrate on immediate effect for angina pectoris [RR 0.96; 95% CI 0.81 to 1.15; 1 trial, n = 80]. In conclusion, oral Panax notoginseng preparation could relieve angina pectoris related symptoms. However, the small sample size and potential bias of most trials influence the convincingness of this conclusion. More rigorous trials with high quality are needed to give high level of evidence, especially for the potential benefit of cardiovascular events.
authors.affiliation: Beijing University of Chinese Medicine, Beijing 100029, China ; Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
authors.forename: Qinghua
authors.initials: Q
authors.lastname: Shang
authors.forename: Hao
authors.initials: H
authors.lastname: Xu
authors.forename: Zhaolan
authors.initials: Z
authors.lastname: Liu
authors.forename: Keji
authors.initials: K
authors.lastname: Chen
authors.forename: Jianping
authors.initials: J
authors.lastname: Liu
references.citation: Chin J Integr Med. 2011 Jan;17(1):11-20
references.pmid: 21258891
references.citation: Cochrane Database Syst Rev. 2008 Oct 08;(4):CD006305
references.pmid: 18843711
references.citation: Chin J Integr Med. 2011 Jan;17(1):21-5
references.pmid: 21258892
references.citation: Cochrane Database Syst Rev. 2010 May 12;(5):CD004468
references.pmid: 20464731
references.citation: J Altern Complement Med. 2008 Jan-Feb;14(1):3-7
references.pmid: 18199020
references.citation: Med Sci Monit. 2006 Jan;12(1):SR1-7
references.pmid: 16369479
references.citation: Chin J Integr Med. 2011 Feb;17(2):83-4
references.pmid: 21390571
references.citation: Zhongguo Zhong Yao Za Zhi. 2008 Dec;33(24):2950-3
references.pmid: 19294859
references.citation: J Agric Food Chem. 2009 Aug 12;57(15):6692-7
references.pmid: 19722574
references.citation: Cochrane Database Syst Rev. 2008 Apr 16;(2):CD004465
references.pmid: 18425903
references.citation: Zhong Yao Cai. 2010 Jan;33(1):89-92
references.pmid: 20518313
references.citation: Chin J Integr Med. 2011 Feb;17(2):88-94
references.pmid: 21390573
references.citation: Cochrane Database Syst Rev. 2008 Jan 23;(1):CD004473
references.pmid: 18254051
references.citation: Cochrane Database Syst Rev. 2006 Oct 18;(4):CD004474
references.pmid: 17054205
references.citation: Acta Pharmacol Sin. 2002 Dec;23(12):1157-62
references.pmid: 12466054